Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 251Neoplasms, Plasma Cell 91Lymphoma, Non-Hodgkin 33Hodgkin Disease 33Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma 29Leukemia 29Immunoglobulin Light-chain Amyloidosis 29Myelodysplastic Syndromes 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Myeloid, Acute 25Lymphoma, Mantle-Cell 20Lymphoma, Follicular 20Myeloproliferative Disorders 19Lymphoma, Large B-Cell, Diffuse 19Lymphoma, B-Cell, Marginal Zone 19Recurrence 17Lymphoma, Large-Cell, Immunoblastic 17Burkitt Lymphoma 17Primary Myelofibrosis 14Congenital Abnormalities 14Anemia, Aplastic 13Waldenstrom Macroglobulinemia 12Leukemia, Myeloid, Chronic-Phase 12Leukemia, Myeloid, Accelerated Phase 12Leukemia, Myelomonocytic, Chronic 11Hematologic Neoplasms 11Graft vs Host Disease 11Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, T-Cell, Cutaneous 9

Interventions

liposomal doxorubicin 1TKN732 1Melphalan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patient Participation × Melphalan × Plasma cell × Clear all
NCT00985907 2020-06-17

DMV

University of California, San Francisco

Phase 1/2 Terminated
13 enrolled 8 charts
Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡